Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph E Tomaszewski

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Plos One|February 4, 2017
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assayJiuping Ji, Yiping Zhang, Christophe E Redon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Designing phase 0 cancer clinical trialsAnthony J Murgo, Shivaani Kummar, Larry Rubinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Tissue-based research in kidney cancer: current challenges and future directionsSabina Signoretti, Gennady Bratslavsky, Frederick M Waldman, et al.
Plos One|January 4, 2013
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissuesThomas D Pfister, Melinda Hollingshead, Robert J Kinders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical UseApurva K Srivastava, Soumya Jaganathan, Laurie Stephen, et al.
Cancer Journal (Sudbury, Mass.)|June 10, 2008
Phase 0 clinical trials: conceptions and misconceptionsShivaani Kummar, Larry Rubinstein, Robert Kinders, et al.
Molecular Interventions|January 18, 2008
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders, Ralph E Parchment, Jay Ji, et al.
Cancer Chemotherapy and Pharmacology|June 30, 2005
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevanceElizabeth R Glaze, Amy L Lambert, Adaline C Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2016
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic ImmunoassaysApurva K Srivastava, Melinda G Hollingshead, Jennifer Weiner, et al.
Toxicology|April 22, 2008
Integration of in vivo and in vitro approaches to characterize the toxicity of Antalarmin, a corticotropin-releasing hormone receptor antagonistThomas L Horn, J Brooks Harder, William D Johnson, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Plos One|February 4, 2017
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assayJiuping Ji, Yiping Zhang, Christophe E Redon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Designing phase 0 cancer clinical trialsAnthony J Murgo, Shivaani Kummar, Larry Rubinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Tissue-based research in kidney cancer: current challenges and future directionsSabina Signoretti, Gennady Bratslavsky, Frederick M Waldman, et al.
Plos One|January 4, 2013
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissuesThomas D Pfister, Melinda Hollingshead, Robert J Kinders, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical UseApurva K Srivastava, Soumya Jaganathan, Laurie Stephen, et al.
Cancer Journal (Sudbury, Mass.)|June 10, 2008
Phase 0 clinical trials: conceptions and misconceptionsShivaani Kummar, Larry Rubinstein, Robert Kinders, et al.
Molecular Interventions|January 18, 2008
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders, Ralph E Parchment, Jay Ji, et al.
Cancer Chemotherapy and Pharmacology|June 30, 2005
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevanceElizabeth R Glaze, Amy L Lambert, Adaline C Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2016
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic ImmunoassaysApurva K Srivastava, Melinda G Hollingshead, Jennifer Weiner, et al.
Toxicology|April 22, 2008
Integration of in vivo and in vitro approaches to characterize the toxicity of Antalarmin, a corticotropin-releasing hormone receptor antagonistThomas L Horn, J Brooks Harder, William D Johnson, et al.
Pageof 5